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ABSTRACT: Lateral flow immunoassays (LFIs) are equipment-free tests that produce
results quickly using small sample volumes. Colored lines appear as the test runs,
indicating the presence of a biomarker. LFIs are ideal in a variety of settings.
Development of these assays can be complicated for small team operations, and tests are
not sufficiently adaptable for low resource settings. If robust point-of-care tests can be
developed on site, they can expand the reach of global diagnostics, improving health
around the world. We report a simple empowering LFI (seLFI) that only requires treated
printer paper and a plastic backing card. This eliminates the use of nitrocellulose
membrane, sample pad, conjugate pad, absorbance pad, and all the required layering
during assembly. Additionally, test and control line antibodies can be applied to this
treated paper by a rollerball pen, allowing on site preparation of the seLFI. The seLFI
is a low-cost, labor-saving, single-sheet diagnostic that performs comparably to
commercially available LFIs. These tests could assist small team operations in
developing versatile tests to use on site, or to resolve complications during
commercialization. They could also be used in low-resource or at-home settings to
personalize tests before running them. We present the proof-of-concept seLFI to improve
the accessibility, robustness and versatility of diagnostics research.
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■ INTRODUCTION
Across the globe, regardless of
age, race, and condition of living, people
struggle to overcome or live with health
challenges. According to the World Health
Organization, the number of patients with
diabetes has risen to 422 million, with 3.7
million deaths caused by high glucose per
year. The World Health Report indicates
that 50,000 people die of infectious
diseases daily, many of which could be
prevented or cured for just one dollar a
person. Approximately 76,000 women
and 500,000 babies die worldwide from
preeclampsia and hypertensive disorders
yearly. In developing countries, women
are seven times more likely to develop
preeclampsia than women in developed
countries. The World Allergy
Organization estimated in 2011 that 3040% of the world’s population
experiences an allergy to one or more
allergens. In a world of chronic disease,
infectious agents, allergies, intolerances,
and health complications, the need for
diagnostic tests is becoming ever greater.
The World Health Organization has
developed a standard for diagnostic tests
called the ASSURED criteria: Affordable,
Sensitive, Specific, User-friendly, Rapid
and robust, Equipment-free, and
Deliverable to end-users. Diagnostic tests
following these criteria allow healthcare
providers with any range of resources to
participate in improving the health of their
patients.
In many situations, lateral flow
immunoassays, or LFIs, are used to
satisfy the ASSURED criteria, bringing
diagnostic tests to even the most resourcerestricted clinics. These equipment-free
tests produce results in 10-20 minutes and
use small sample volumes. LFIs are easy
to run, and the results are straightforward
to interpret; colored lines appear as the

tests run, indicating the presence of a
biomarker in a sample. Although
traditional LFIs seem ideal for lowresource settings, additional challenges
remain. By definition, low-resource areas
struggle with poverty, and maintaining a
strong medical front against epidemics is
inherently expensive. While LFIs are
manageable for first-world patients and
clinics to purchase, affording these preassembled products can be difficult for
small team operations globally.
In any setting, a diagnostic test
needs to be non-invasive and fast,
delivering quick results at the point of
care (POC). In low-resource settings, a
clinic might be without advanced training,
equipment, or electricity, so it is critical
that tests are easy to understand, run, and
interpret. To reduce costs in low-resource
settings, the tests also need to be easy,
straightforward, and inexpensive to
assemble; lowering the manufacturing
costs reduces the cost of the test. To
manufacture traditional LFI tests, a wellequipped lab would have a striper (a
machine that immobilizes antibodies to
nitrocellulose membrane), a laminator (a
machine that aids the assembly of the
layered lateral flow cards), and a test
shear (a machine that cuts laminated cards
into individual tests). A striper costs
anywhere from $6,500 to $46,500
(ClaremontBio and BioDot), along with
$6,100 to $8,625 for a laminator (BioDot
and Kinematic Automation), and $13,600
to $16,790 for a test shear (BioDot and
Kinematic Automation). On average, the
start-up cost of a small-scale lateral flow
research lab is $47,520 for this equipment
and materials like nitrocellulose
membrane, plastic backing cards,
conjugate, sample and absorbance pads.
For small team operations,
especially those new to diagnostics
research, this up-front cost that is almost
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too great. For labs and clinics in lowresource settings, this equipment is too
expensive, leaving them to source
diagnostic tests from larger companies
that were able to afford the start-up cost.
Making assay development and diagnostic
test manufacturing more accessible to
these groups would promote good health
practices, research, and scientific standing
in these areas.
We introduce a new LFI platform
that lowers the barrier of assay
development and manufacturing for lowresource labs and clinics, as well as for
small team operations. This platform,
referred to as the “simple empowering
lateral flow immunoassay” (seLFI), uses
chemically treated paper attached on a
plastic backing support, reducing the
many layers of a traditional LFI to a
single sheet of paper. Like the traditional
LFI, the seLFI uses capillary action,
conjugated antibodies, test and control
lines, and a greatly simplified chase buffer
to detect a biomarker.
We report the development of the
seLFI, an LFI whose manufacture only
requires treated printer paper and a
supportive backing. This eliminates the
need for nitrocellulose paper, sample pad,
conjugate pad, absorbance pad and all
assembly associated with these layers.
Additionally, test and control line
antibodies can be applied to this paper by
an antibody pen, making the seLFI both
adaptable and straightforward to develop.
The seLFI is a low-cost, labor-saving,
single sheet of treated paper that produces
results comparable to commercially
available LFIs. In this paper, we describe
a seLFI test developed to detect hCG in
different sample matrices (spiked human
urine, fetal bovine serum) at levels of
1:103 in under five minutes. These tests
could assist individual researchers and
small team operations in developing

personalized, on-site diagnostics. We
present the proof-of-concept seLFI to
improve the production, robustness, and
versatility of diagnostics in small team
and low-resource operations.
A traditional LFI is made up of
several layered materials adhered to a
plastic backing card (Figure 1). These
materials consist of a sample pad, a
conjugate pad, a nitrocellulose membrane,
an absorbance pad, and often require tape
allowing compression between layers to
facilitate flow (Fenton, et al.). Each of
these layered materials are customizable,
Traditional LFI
Sample
Sample pad

Conjugatepad

Nitrocellulose
membrane

Test line

Absorbance pad

Plastic backing card
Control line

Treated
printer paper

seLFI

Test line

Control line

Plastic backing card

Figure 1. Traditional LFI to seLFI.
The multiple layers of an LFI combine to allow
the flow of a sample through the diagnostic. The
sample pad wicks up the sample, delivering it to
the conjugate pad. Here, the sample interacts
with the conjugated antibodies in the pad, and
any biomarkers present bind to the conjugated
antibody. The whole sample continues through
the nitrocellulose membrane, where any
biomarker/conjugated antibody complexes bind
the test line and left over conjugated antibodies
bind to the control line. The absorbance pad
ensures the complete flow of the sample through
the test, drawing it continually upward. The
seLFI removes all of these layers, relying on the
capillary action of treated printer paper to draw
the sample, which is previously mixed with
conjugated antibody, past the test and control
lines, producing similar binding.
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with different types of materials to choose
from, with varying treatments that can be
applied. Often, simply changing the type
of material or the treatment applied to it
can determine if the LFI runs successfully,
or if it fails. The materials can vary in size
and in overlap, with some tests being
long, others being thin, some with their
layers overlapping 2.5 mm, 1 mm. Each
test is different, with no simple,
streamlined pathway of development.
While developing an LFI, labs experiment
with these many variations, and expend
two valuable resources: time and funding.
Manufacturing developed tests requires
additional time and funding.
To streamline time and funding,
we propose reducing the layers of the LFI
from at least five layers to two: a plastic
backing card and treated paper.
Eliminating the sample pad, conjugate
pad, nitrocellulose membrane, absorbance
pad, and tape reduces the cost of materials
significantly. The time spent working
through each of these materials to find the
best fit can be dedicated to developing the
test in other areas. Manufacturing tests no
longer involves overlapping layers by
exact measurements and pressing the
overlaps together with tape or a cartridge,
but rather securing treated paper to a
plastic backing card. The expensive
machines used to stripe the tests are
replaced by a rollerball pen filled with
antibody ink. Treatment of each material
goes from a multitude of options to one:
modifying the paper to behave like
nitrocellulose membrane.

■ METHODS
Progression to “Sandwich Model”
Traditional LFI tests follow the
“sandwich model”, where a conjugated
antibody binds to the target biomarker.

This conjugated antibody-biomarker
complex binds to unconjugated antibody
that is secured to the nitrocellulose layer
as the test line. The test line constitutes
unconjugated antibodies that recognize
the conjugated antibody. The three
proteins (unconjugated antibody, antigen,
and conjugated antibody) form what is
called the “sandwich model” and is the
clinically relevant goal when developing a
diagnostic test.
To begin seLFI development, we
focused on the simplest version of this
clinically relevant model, termed “tier
one”. A tier one test was purposed to
answer two questions:
1. Would protein remain bound to the
modified paper test?
2. Could the bound protein withstand the
friction of fluid flow, or would
capillary action dislodge the bound
protein?
To answer these questions, we built a
minimalistic test with only one protein.
This was done by modifying printer
paper, either by nitration or by aldehydefunctionalization, securing it to a plastic
backing card, and dividing it into test
strips. The test strips were striped with
conjugated antibody (⍺-hCG beta
antibody in goat, gold colloid, Fitzgerald)
and were subjected to capillary flow of
5% dry milk TBS-T buffer. Following the
tier one test, a tier two test was developed.
A tier two test built upon this
model, adding a protein to the test. Tier
two would answer the following question:
1. Could a test or control line capture
antibodies or other proteins as they
flow past in a buffer medium?
2. If so, will the captured proteins remain
bound as additional sample and buffer
clears the test or control lines?
Tier two tests were made with both
nitrated printer paper and aldehyde13

functionalized printer paper, then
compared to see which paper treatment
performed best. Modified printer paper
was striped with hCG protein (EMD
Millipore) and allowed to dry. 5% dry
milk TBS-T buffer spiked with conjugated
antibody (⍺-hCG beta antibody in goat,
gold colloid, Fitzgerald) was used to
induce capillary action. Since we stopped
using nitrated printer paper after tier two,
the details of this method are included in
the section dedicated to nitrated printer
paper.
Tier three was built as a final
phase preliminary test, answering the
standard questions:
1. Could a line of antibodies capture a
protein-conjugate complex?
2. Could a line of antibodies capture the
conjugated antibody?
At this point in our research, nitrated
printer paper had ceased to be a focus,
whereas aldehyde-functionalized printer
paper became our first choice for the
seLFI. Therefore, our tier three tests were
developed on aldehyde-functionalized
printer paper only, and not nitrated printer
paper. These tests were first made with
only a test line: a stripe of ⍺-hCG (⍺-hCG
alpha antibody in goat, MyBioSource)
that would be met with a complex of hCG
(EMD Millipore) and conjugated antibody
(⍺-hCG beta antibody in goat, gold
colloid, Fitzgerald). We then developed a
tier three test with only a control line: a
stripe of anti-host antibody (rabbit antigoat, Fitzgerald, MyBioSource) that
would be met with conjugated antibody
(⍺-hCG beta antibody in goat, gold
colloid, Fitzgerald). Since tier three was
our clinically relevant goal, the details are
outlined in the following section
dedicated to aldehyde-functionalized
printer paper.

Nitrated Printer Paper
Nitrocellulose membranes use
hydrophobic interactions to bind to
proteins. These hydrophobic interactions
are strong, and once bound, only extreme
measures can remove proteins from
nitrocellulose membrane. Therefore, when
nitrocellulose membrane is striped with
test and control antibodies, they remain
fixed. The surrounding active sites on the
membrane are blocked, and additional
proteins, such as those in a biological
sample, can flow through the membrane,
only binding to specific antibodies with
which they pair. Compared to
nitrocellulose membrane, paper is a lowcost solution, but it must be modified to
secure proteins and keep them from
drifting as biological sample and buffer
flow through the paper. Nitration was the
first method explored to modify paper to
act like nitrocellulose membrane. Equal
parts of nitric and sulfuric acid were
carefully combined and stored at low
temperatures in a small glass vial. Printer
paper (75 g/m2, 92 bright, Target) was
attached to a plastic backing card and cut
into 5.0 mm x 34.5 mm strips. The chilled
acid mixture was pipetted across the
middle zone of the paper strips to create a
fine line (2.0-3.0 mm) that would hold the
test protein. After the acid mixture was
deposited and allowed to absorb, the
paper strips were run under continuous
water for five minutes, then incubated
with sodium bicarbonate and water under
shaking for an additional five minutes.
After neutralization, the nitrated paper
strips could dry at room temperature and
were stored in a sealed bag with desiccant
packs at room temperature.
In the first phase of research, hCG
was acting as the test protein, with
conjugated ⍺-hCG acting as the
biomarker spiking the buffer. This was a
“first-step” toward a more clinically
14

relevant “sandwich” model, with
antibodies as the test and control proteins,
and unconjugated proteins acting as the
biomarker. Initially, the tests were barebones simple, involving only hCG and
conjugated ⍺-hCG. To prepare the test
strips, 1.0 μL of hCG at 1.0 mg/mL (the
test protein in this model) was pipetted
along the nitrated zone and allowed to dry
and bind. In order to prevent false
positives, the active sites of the nitrated
zone were blocked by pipetting 3 μL of a
5% solution of dry milk in TBS-T onto
and around the edges of the test zone.
After drying, the tests were ready to run.
Aldehyde-functionalized Printer Paper
Another successful method of
securing proteins to paper was developed
by Badu-Tawaiah et al. This method takes
cellulose and creates aldehyde groups
through a process of incubating the paper
in a solution of KIO4. Those aldehyde
groups can then form Schiff bases with
proteins that contact the paper, similar to
nitrocellulose. In this method, one sheet
of printer paper was placed in a 0.03 M
solution of KIO4. The paper was then
soaked for 2 hours at 65°C. After
treatment, the paper was rinsed three
times in fresh deionized water, and then
allowed to dry overnight at 35°C.
Once the paper was dry, antibodies
were added to the paper in test and control
lines. The test line antibodies and control
line antibodies were placed directly onto
the aldehyde functionalized paper using a
straight edge to guide the line and a 10 μL
syringe to apply the antibody (1.0
mg/mL). Later, syringes would be
replaced with antibody pens, which are
discussed hereafter. Since the entire
paper’s surface was functionalized after
treatment, the strips were blocked with
5% dry milk blocking buffer in water to

ensure that the paper would not have open
active sites. After the blocking, the paper
was dried, then placed onto a plastic
backing card. Once attached to the card,
the paper was cut into 5.0 mm x 34.5 mm
strips. The process of creating aldehyde
functionalized paper is simple and has the
potential to be delivered to the end user
ready to be striped and blocked.
To run the test strips, 90.0 µL of
5% dry milk solution in TBS-T was added
to 14 2.0 mL microcentrifuge tubes.
Seven of the tubes acted as positive
controls: six for the seLFI, and one for the
commercially available pregnancy test. To
these seven tubes, 1.0 µL of hCG (1.0
mg/mL) was added to each tube
separately and mixed gently with a
pipette. The other seven tubes acted as
negative controls, with six for the seLFI,
and the seventh for the commercially
available pregnancy test. 10.0 µL of gold
nanoparticle (AuNP) conjugated goat ⍺hCG antibodies were added to each tube
separately and mixed gently with a
pipette. After preparing these samples, test
strips were placed into each tube and
allowed to run via capillary action.
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Antibody Pens
Aldehyde-functionalized paper
proved to be a strong, flexible,
inexpensive alternative to nitrocellulose.
Striping this paper with test and control
antibodies would traditionally be done
with an automated dispenser. However,
the goal of this project excluded the use of
expensive equipment and electricity, since
neither are currently feasible in lowresource areas. Even other low-cost
options such as using a printer or a simple
X-Y plotter required electricity, and it
became clear that the target demographic
would require a more manual technique.
The best way to precisely deliver a
substance to a surface without electricity
is with a writing instrument. Research led
to filling felt-tipped markers, brush pens,
ballpoint pens, and paint pens with an
antibody solution “ink”, with the most
success of delivery being found in a
rollerball pen. These rollerball pens can
be filled with virtually any antibody ink
and are able to draw lines of antibodies
onto the aldehyde functionalized paper,
producing the control and test lines for
many different kinds of tests. We found
that J. Herbin refillable rollerball pens
(Figure 2) were best suited for delivering
antibody ink since they used a wick to
draw up the ink and used a refillable
piston cartridge to hold ink (Kaweco Mini
Piston Converter). This made it easy to
test, clean, and reuse the pen with
different types of antibodies. This method
of delivery promotes user-specific and
diverse diagnostic tests for a variety of
settings—including low-resource settings
and small team operations.
To test feasibility, the piston
cartridges were filled with rabbit ⍺-goat
antibodies and goat ⍺-hCG antibodies.
The control pen (goat ⍺-hCG) was used to
write on aldehyde functionalized paper
and nitrocellulose. Once the protein ink

D

E

Figure 2. Antibody Pen
Pictured is a sequential explosion of the
antibody rollerball pen. A) shows the pen
completely assembled and capped. B) shows the
pen uncapped, exposing the tip of the rollerball
pen. C) shows the body unscrewed from the tip
housing, showing how the piston cartridge
attaches securely to the tip housing, connecting
to the wick. D) shows the depressed piston
cartridge detached from the tip housing,
exposing the faint outline of the white wick in
the tip housing. E) shows the same, but with the
piston cartridge completely extended. The piston
cartridge holds the antibody ink, which is
carried to the tip of the rollerball pen through a
wick when the two are properly connected. Each
part can be cleaned and reused with new or
different antibody when the user desires.

had dried, the blots were blocked together
with 5% dry milk TBS-T buffer at 25℃
while shaking for 1 hour. After rinsing,
the blots were incubated in similar
conditions with TBS and 60 𝜇L hCG for 1
hour. After this incubation, the blots were
16

rinsed and incubated with 400 𝜇L AuNPconjugated goat ⍺-hCG antibodies under
similar conditions for 1 hour. The blots
were then rinsed and dried.
Additional tests were done to
determine the antibody pen’s longevity.
The antibody pen piston cartridge was
filled with 100 𝜇L of rabbit ⍺-goat
antibodies, secured to the pen, and then
was used to draw several straight lines of
antibody ink on a single sheet of paper
until the pen ran dry. The paper was then
blocked for 1 hour in 5% dry milk
solution in TBS-T, washed in deionized
water, then incubated with 400 𝜇L AuNPconjugated goat ⍺-hCG antibodies in TBS
under shaking for 1 hour. The paper was
removed, rinsed with deionized water, and
allowed to dry. The observed lines were
measured for length, determining the
approximate number of tests 100 𝜇L of
antibody in the antibody pen could make.
Testing in Urine
Although the seLFI had proven its
potential in a protein-spiked sample
buffer, a clinically relevant diagnostic
would need to perform in biological
samples. Testing the seLFI in biological
samples began with urine, due to
simplicity of training, collection, and
storage. To run the test strips, 90.0 µL of
urine were added to eight 2.0 mL
microcentrifuge tubes. 1.0 µL of hCG (1.0
mg/mL) was added to the first four tubes
separately and mixed gently with a
pipette, constituting our positive samples.
An additional positive control was
performed with a commercially available
pregnancy test, run with the fourth tube
according to the package directions. The
remaining four tubes were left without
hCG, constituting our negative samples.
An additional negative control was run
using a second commercially available

pregnancy test. To the remaining six tubes
(both positive and negative samples), 10.0
µL of AuNP-conjugated goat ⍺-hCG
antibodies were added to each tube
separately and mixed gently with a
pipette. After preparing these urine
samples, previously prepared aldehyde
functionalized test strips were placed into
each tube and allowed to run via capillary
action.
Testing in Serum
Another clinically relevant goal
was to test the seLFI in serum. 90.0 μL of
fetal bovine serum (FBS) were added to
eight 2.0 mL microcentrifuge tubes. 1.0
μL of hCG (1 mg/mL) was added to the
first four tubes separately and mixed
gently with a pipette, constituting the
positive samples. An additional positive
control was performed with a
commercially available pregnancy test,
run with the sample in the fourth tube
according to the package directions. The
remaining four tubes were left without
hCG, constituting the negative samples.
An additional negative control was run
using a second commercially available
pregnancy test. To the remaining six tubes
(both positive and negative samples), 10.0
μL of AuNP-conjugated goat α-hCG
antibodies were added to each tube
separately and mixed gently with a
pipette. After preparing these FBS
samples, previously prepared aldehyde
functionalized test strips were placed into
each tube and allowed to run via capillary
action.
Limit of Detection
A lateral flow immunoassay must
detect a biomarker; furthermore, it must
detect the correct levels of that biomarker
in the sample. Up until this point, we had
been loading a large amount of biomarker
17

(1 𝜇L of 1 mg/mL hCG) into sample
buffer to build a working preliminary
seLFI. To establish a working credible
seLFI, we had to determine the limit of
detection. The goal was to observe the
lowest level of biomarker the seLFI could
detect, especially in a way that the lowest
level could be read by the human eye. Our
desired outcome was for the seLFI to
detect the concentration of hCG in urine
during pregnancy, or 2.5 µg/mL.
To prepare the test runs, a serial
dilution was set up in six dilutions. 90 µL
of 5% dry milk solution in TBS-T was
added to seven 2 mL microcentrifuge
tubes. 10 µL of hCG (1 mg/mL
concentration, or 1:1) was added to and
mixed in the first dilution, resulting in
1:10 hCG concentration. 10 µL of
solution was removed from the first
dilution, added to the second
microcentrifuge tube and gently mixed,
resulting in a 1:102 hCG concentration.
This process was repeated until six tubes
contained hCG ranging from 1:10 to 1:106
concentrations. The final tube was left
without hCG and served as a negative
control.
This serial dilution was repeated
three times in additional microcentrifuge
tubes: two of the sets of serial dilutions
acted as replicates for the original
dilution, and one set of serial dilutions
would be used to run commercially
available pregnancy tests as a positive
control. These commercially available
tests were run according to the package
directions, using each tube separately for
a total of six positive control tests. The
final tube, having no hCG, served as the
negative control.
In the remaining three sets of
tubes, 10 µL of AuNP-conjugated goat αhCG was added to and gently mixed in
each separate dilution. After preparing
these dilution samples, previously

prepared aldehyde functionalized test
strips were placed into each tube and
allowed to run via capillary action.
This experimental set-up was
repeated to test the seLFI’s limit of
detection in urine, replacing the milk
chase buffer volume with the same
volume of urine, keeping all other
conditions the same.

■ RESULTS
Nitrated Printer Paper
In hopes of simplifying and
reducing the cost of the traditional LFI by
eliminating the sample pad, conjugate pad
and absorbent pad, a low-cost format that
was friendly to low-resource areas, the
single-sheet seLFI, was developed. This
experiment tested whether the seLFI
format could support stationary antibodyantigen binding at the “test line”, like the
traditional LFI. After nitrating the printer
paper, striping with antibody, and
performing positive control seLFI tests,
some encouraging results followed. The
running buffer was entirely absorbed by
the seLFI test strip, and capillary action
took the conjugated ⍺-hCG past the test
line of hCG protein, which was bound to
the modified area of the test strip. Binding
between antigen and conjugated antibody
occurred, similar to a traditional LFI
sandwich format. Figure 3 shows the
genuine promise of performing a
diagnostic test using only one layer of
treated printer paper. The nitrated zone
acted as a pseudo test line (the first
antigen and conjugated antibody model
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the zone, rather than directly through it.
Notwithstanding the practice of blocking
around the nitrated area after striping with
antibody, negative tests were inconsistent
(not pictured). Outside of test
performance, test manufacture was risky
and inconvenient, due to the use of strong
acids. With these challenges and dangers,
it was decided to pursue an alternative to
nitrated printer paper.
Figure 3. seLFI with Nitration Method
Nitrated seLFI test strips were made with
printer paper and plastic backing cards. Using
a 1:1 solution of nitric and sulfuric acids, the
printer paper was chemically modified to bind
proteins securely. After being cut into 5.0 mm
x 34.5 mm strips, 1 μL of 1.0 mg/mL hCG was
deposited on and bound to the nitrated middle
portion of the strips, and the remaining area of
the strips were blocked with a 5% dry milk
solution in TBS-T to prevent non-specific
binding. AuNP-conjugated ⍺-hCG was run as
the “sample”. After the tests had run, red lines
could be seen, indicating binding between
hCG and ⍺-hCG. The weaknesses of this
model include impracticality of assembly,
irregular binding, and a slight hydrophobic
barrier that appears at the nitrated zone,
preventing complete flow.

used was not a true test line), presenting a
visual positive result. These visual results
indicated that the modified areas of the
paper functioned akin to nitrocellulose;
stationary test lines on printer paper can
be maintained even after the introduction
of running buffer and sample flow.
Despite the preliminary success of
these elementary test results, several
points were concerning. Visually, the
results were diffuse and nonuniform,
making it difficult for technicians to
distinguish a positive result from a
negative result. Each test produced a
dramatically different result, presenting a
challenge to the tests’ reliability. On
several of the tests, the nitrated zone
behaved as a hydrophobic barrier,
encouraging the sample to flow around

Aldehyde-functionalized Printer Paper
In a safe and convenient
alternative to nitrated printer paper, the
method of Badu-Tawaiah et al. was used
to aldehyde-functionalize printer paper.
Printer paper was treated with KIO4,
separate lines of test and control
antibodies were striped, and the paper was
blocked and cut into test strips. Running
the tests with positive and negative
samples (5% dry milk solution in TBS-T
with and without hCG) produced clear,
uniform, and legible results (Figure 4).
These results demonstrate the seLFI’s
ability to compare to traditional LFI
results, in speed, reliability, and
specificity.
In the positive seLFI results
(Figure 4: A), the milk chase buffer,
AuNP ⍺-hCG, and hCG were drawn up
via capillary action, crossing the entire
test, including the test and control lines.
The hCG/AuNP ⍺-hCG complex
remained bound to the test line, and the
AuNP ⍺-hCG remained bound to the
control line, resulting in the visual result
of two pink lines. In the negative seLFI
results (Figure 4: B), the chase buffer and
AuNP ⍺-hCG ran through the entire test,
crossing both the test and control lines.
There was no hCG/AuNP ⍺-hCG
complex, so nothing bound to the test line,
but the AuNP ⍺-hCG remained bound to
the control line, indicating a valid test.
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Figure 4. Aldehyde-functionalized
seLFI Strips.
Half-strips were prepared with a 0.03 M
solution of KIO4 and heat, then striped with
lines of control (top line) and test (bottom line)
antibodies. The striped paper was blocked and
cut into strips, then the individual tests were
run. A) Positive tests were performed with 30
μL of 5% dry milk buffer, 10 μL of gold
nanoparticle conjugated ⍺-hCG, and 1 μL of 1
mg/mL hCG. Results are clear, with both the
control and test lines showing specific binding.
B) In turn, the negative tests were performed
under similar conditions, with the exception of
hCG. As expected, only the control line
showed specific binding, with a blank test line
indicating the absence of hCG. C) Additional
commercially produced positive controls were
run under similar conditions to verify the
positive and negative seLFIs.

This yielded the visual result of one pink
line. The commercially available
pregnancy tests (Figure 4: C) show the
negative control (left) and positive control
(right). These tests show an intensity of
color in the results and a low background
that surpassed the seLFI tests. Though the
seLFI tests exhibit potential in accuracy,
specificity, and visual readability,
optimization was needed.
Antibody Pen
The antibody pen was used to
draw letters on to aldehyde-functionalized
paper using goat ⍺-hCG antibody ink.
These markings could be seen as wet lines
until they dried; after drying, the writing
disappeared entirely. The consequent
steps in the experiment—blocking,
incubating with hCG, then incubating

with AuNP ⍺-hCG—were intended to
facilitate a “sandwich” complex between
the invisible goat ⍺-hCG that was drawn
onto the paper, the suspended hCG, and
the suspended AuNP ⍺-hCG. This test
would determine if the antibody pen
allowed for proteins to pass through the
system without being damaged, and if the
delivery would be detailed, even, and
precise (Figure 5).

Figure 5. Antibody Pen Precision and Efficacy
To determine if the antibody pens would write
evenly and precisely without damaging the
antibodies in the ink, the piston cartridge was
filled with rabbit ⍺-goat antibodies. It was then
used to write on aldehyde functionalized paper
and nitrocellulose. Once the protein ink had
dried, the blots were blocked together with 5%
dry milk TBS-T buffer at 25℃ while shaking
for 1 hour. After rinsing, the blots were
incubated in similar conditions with TBS and 60
𝜇L hCG for 1 hour. After this incubation, the
blots were rinsed and incubated with 400 𝜇L
AuNP-conjugated goat ⍺-hCG antibodies under
similar conditions for 1 hour. The blots were
then rinsed and dried. A and B show results on
nitrocellulose, while C and D show results on
aldehyde-functionalized paper. A and C were
written by technician A, and B and D were
written by technician B.
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These completed tests presented
clear, uniform, legible lines. For both
aldehyde-functionalized paper and
nitrocellulose paper, the antibody delivery
is so detailed that the differences in
handwriting between the two technicians
can be identified. When run under
identical conditions, the aldehyde
functionalized paper produced a clearer,
darker result than the nitrocellulose paper.
The pen has been licensed to DCN
Diagnostics and is currently being
developed to be included in their LFI
starter kits.
The second test determined the
lifetime of 100 μL of antibody ink in the
pen (Figure 6). After drawing, blocking,
incubating, and drying, the lines were
measured to project the total number of
tests 100 μL of antibody could produce. A
total of 5,588 mm was measured before
the integrity of the line began to break up,
leaving the rest unmeasured for the sake
of quality control. This length would

Figure 6. Antibody Pen Extinction Test
This test was designed to better understand the
lifetime of antibody ink in the pen. 100 𝜇L of
rabbit ⍺-goat antibodies were used to fill the
piston cartridge, then drawn out in straight
lines until the antibody ink ran out. The paper
was then blocked for 1 hour in 5% dry milk
solution in TBS-T, washed in deionized water,
then incubated with 400 𝜇L AuNP-conjugated
goat ⍺-hCG antibodies in TBS under shaking
for 1 hour. The paper was removed, rinsed
with deionized water, and allowed to dry. The
lines were later measured and broken down
into an approximate yield of tests.

result in approximately 1,117 tests. These
tests indicate that the antibody pen is
feasible with the low-cost, machine-free
manufacturing system required by a lowresource lab or clinic.
Testing in Urine
Testing the seLFI in urine would
expand the platform from a research
relevant diagnostic to a clinically relevant
diagnostic. After running the hCG seLFI
tests in milk buffer successfully, we
reproduced the testing procedures for
testing in urine, simply replacing the milk
chase buffer with the same amount of
urine (Figure 7). Production of the tests
and the amounts of hCG and AuNP ⍺hCG remained the same as the tests run in
milk chase buffer. The tests performed

Figure 7. Aldehyde-functionalized seLFI Strips
in Urine
Half-strips were prepared according to the
aldehyde-functionalization method. Positive
tests (left) were performed with 90 μL of urine,
10 μL of AuNP ⍺-hCG, and 1 μL of 1 mg/mL
hCG. Results are clear, with both the control
and test lines showing specific binding.
Negative tests (right) were performed under
similar conditions, without the addition of
hCG. As expected, only the control line
showed specific binding, with a blank test line
indicating the absence of hCG. Commercially
available (center) positive and negative
controls were run under according to package
directions to validate the seLFI results.
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exceptionally well, revealing clear test
and control lines in the positive samples,
and clear control lines in the negative
samples. The tests ran significantly faster
in urine than they did in milk chase
buffer: a quick 2 minutes compared to 20
minutes.
Testing in Serum
With encouraging results from
testing in urine samples, the next step was
to test the seLFI in fetal bovine serum
(Figure 8). Like the urine tests, we simply
replaced the milk chase buffer with the
same amount of FBS, keeping all other
variables consistent. These tests still
showed promise, presenting consistent
positive and negative results, and taking
only about 2 minutes to complete.

Figure 8. Aldehyde-functionalized seLFI Strips
in Fetal Bovine Serum
Half-strips were prepared according to the
aldehyde-functionalization method. Positive
tests (left) were performed with 90 μL of fetal
bovine serum, 10 μL of AuNP ⍺-hCG, and 1
μL of 1 mg/mL hCG. Results are clear, with
both the control and test lines showing specific
binding. Negative tests (right) were performed
under similar conditions, without the addition
of hCG. As expected, only the control line
showed specific binding, with a blank test line
indicating the absence of hCG. Commercially
available (center) positive and negative
controls were run under according to package
directions to validate the seLFI results.
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Limit of Detection
Finding the seLFI’s limit of
detection would allow for a side-by-side
comparison of the seLFI’s sensitivity and
the sensitivity of commercially available
tests. Ideally, the seLFI would be able to

detect hCG at the level of 1:104 in order to
detect 2.5 ng/mL of hCG in a positive
urine sample. The seLFI consistently
bound hCG at concentrations of 1:102 to
1:103, with unreliable, faint binding at
1:104 (Figure 9). Interestingly, a
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Figure 9. Aldehyde-functionalized seLFI Limit of Detection
Half-strips were prepared according to the aldehyde-functionalization method. All samples were
prepared in similar fashion, with 90 L of sample in each tube and 10 L of hCG used to make a serial
dilution of values from 1:10 to 1:106. These were repeated three times to make a total of four runs: three
dedicated to testing the seLFI, and one dedicated as a control with commercially available pregnancy
tests. A-C show results with milk buffer, with D as the control. E-G show results with urine, with H as
the control.
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concentration of hCG at 1:10 resulted in
weak test lines as well. Acknowledging
the inconsistent binding at 1:10 and 1:104
and beyond, we determine the seLFI limit
of detection to be between 1:102 and
1:103. These results were consistent across
all three trials for both milk chase buffer
(Figure 9 A-D) and urine samples
(Figure 9 E-H).

■ DISCUSSION
The aldehyde-functionalized paper
is a low-cost, safe, flexible replacement
for nitrocellulose.
For small labs or clinics with low funding
or few resources, purchasing
manufacturing machinery to make tests
for labs, or purchasing pre-made tests for
clinics is financially challenging. Having
an electricity-free instrument that could be
used to make diagnostic tests for research
or for clinical use would serve those
populations well. The antibody pen
delivers similar results at a small scale.
The low price and simple maintenance
and use of the pen lends itself well to
diagnostic development, as well as fast
test manufacture for in-field use.
Diagnostic tests use biological
samples to detect the presence of
biomarkers in the sample, becoming a tool
to aid in diagnosis and treatment of
diseases and conditions. Biological
samples range from whole blood to
serum, tears to saliva, urine to feces, and
many more. The ability to detect
biomarkers in biological samples was key
to the success of the seLFI, allowing it to
function as a diagnostic tool. Due to the
presence of hCG in urine during
pregnancy, it was encouraging to observe
the seLFI’s results when tested in urine. A
short running time with clear, legible
results opens the possibility of developing

a test for a different biomarker in a
different sample type. Although urine has
a connection to the biomarker used in this
study, we chose to test for hCG added into
serum during sample preparation. The
purpose of these tests was to explore the
possibility of testing in different types of
samples, while still working with a
biomarker and antibodies that we were
familiar with. The results of the seLFI
serum tests were likewise encouraging
and led us to plan to test the seLFI in
whole blood and saliva. The goal is to
prove the seLFI platform in as many
biological samples as possible, in order to
establish its potential as a new,
innovative, and versatile diagnostic
platform.
In order to be an effective test, the
seLFI’s sensitivity would need to achieve
a limit of detection of 1:104. In order to
improve sensitivity, a few avenues will be
pursued. The first would be to simply
increase the amount of AuNP ⍺-hCG used
while running the test. This would
saturate the available hCG, increasing the
intensity of the test line, despite the lower
levels of protein in the sample. Another
avenue involves antibody-antigen
pairings. With a fade-out at 1:104
concentration of hCG, the issue is
between the ⍺-hCG, hCG, and AuNP ⍺hCG sandwich complex. Finding a variety
of these proteins and would allow us to
set up a protein matrix. This would
involve a series of blot tests, each with the
same ⍺-hCG variety blotted onto a small
square of aldehyde-functionalized paper,
then blocked separately. Each of the blots
would then be incubated with the same
variety of hCG, then washed, then each
blot would be incubated with a different
variety of AuNP ⍺-hCG. These blot
matrices would be repeated, adjusting the
varieties of ⍺-hCG, hCG, and AuNP ⍺hCG appropriately until an ideal match is
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discovered. This ideal match would
indicate the proteins that have the highest
binding affinity, increasing the amount of
hCG binding to both ⍺-hCG and AuNP ⍺hCG, strengthening the intensity of the
test line. An alternative avenue would be
to increase the concentration of ⍺-hCG on
the test line, so as to capture more hCGAuNP ⍺-hCG complexes, raising the level
of sensitivity.

The possibility of a false-negative
would need to be addressed, considering
the weak, unreliable binding at
concentrations of hCG at 1:10. To prevent
a false-negative, protein interactions at
concentrations of 1:10 would need to be
studied and understood more thoroughly
in order to plan experiments and adjust
the test and its procedures.
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